Semler Scientific Inc (SMLR) USD0.001

Sell:$37.00Buy:$38.64$2.40 (6.97%)

Prices delayed by at least 15 minutes
Sell:$37.00
Buy:$38.64
Change:$2.40 (6.97%)
Prices delayed by at least 15 minutes
Sell:$37.00
Buy:$38.64
Change:$2.40 (6.97%)
Prices delayed by at least 15 minutes

Company Information

About this company

Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.

Key people

Douglas Murphy Chutorian
Chief Executive Officer, Director
Renae Cormier
Chief Financial Officer
Eric Semler
Independent Chairman of the Board
William H.C. Chang
Independent Director
Daniel S. Messina
Independent Director
Click to see more

Key facts

  • EPIC
    SMLR
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Medical Equipment & Supplies
  • ISIN
    US81684M1045
  • Market cap
    $328.97m
  • Employees
    79
  • Shares in issue
    9.81m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.